Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

导出原文传递

翻译打印收藏纠错

作者： Winqvist, Maria ^[1] ; Mozaffari, Fariba ^[2] ; Palma, Marzia ; Sylvan, Sandra Eketorp ; Hansson, Lotta ; Mellstedt, Hakan ; Osterborg, Anders ; Lundin, Jeanette

作者单位： Karolinska Univ Hosp, Dept Hematol, S-17176 Stockholm, Sweden ^[1] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden ^[2]

关键词 Chronic lymphocytic leukemia Lenalidomide Alemtuzumab T cells Immune checkpoints

发布时间 2018-05-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Cancer Immunology and Immunotherapy

2017年66卷1期

91-102页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

Cancer Immunology and Immunotherapy

相似文献

Cancer Immunology and Immunotherapy

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

Cancer Immunology and Immunotherapy

相似文献

Cancer Immunology and Immunotherapy

相关期刊

检索历史清除